immatics biotechnologies GmbH


To fight cancer, Immatics combines the discovery of true targets with the development of the right T cell receptors for immunotherapies.

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.



Activity Biotechnology, Development, Health, Oncology, Pharmacy


Harpreet Singh, Ph.D. - Chief Executive Officer
Arnd Christ - Chief Financial Officer
Carsten Reinhardt, M.D., Ph.D. - Chief Development Officer
Cedrik Britten, M.D. - Chief Medical Officer
Rainer Kramer, Ph.D. - Chief Business Officer
Steffen Walter, Ph.D. - Chief Technology Officer
Toni Weinschenk, Ph.D. - Chief Innovation Officer

Year of foundation




Supervisory board

Peter Chambré (Chairman)
Adam Stone
Eliot Forster, Ph.D.
Heather Maison
Michael Atieh
Paul Carter, FCMA

Academic board

Cassian Yee, M.D. - MD Anderson Cancer Center, US
Christop Huber, Ph.D - Johannes Gutenberg University, Germany
Crystal Mackall, M.D. - Stanford University, US
Gwendolyn Binder, Ph.D. - Cabaletta Bio, US
Hans-Georg Rammensee, Ph.D. - Eberhard Karls University, Germany
Hidde Ploegh, Ph.D. - Boston Children's Hospital, US
Patrick Hwu, M.D. - MD Anderson Cancer Center US
Roland Kontermann, Ph.D. - University of Stuttgart, Germany



BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor – peptide-HLA interactions

T cell therapies open up promising therapeutic perspectives and are currently still limited to only a few specific areas of application. In the field of oncology, two therapeutics…


Immatics Announces Changes to its Board of Directors

Tuebingen, Germany and Houston, Texas, May 26, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development…


Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model IMA402 targets…


Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Company to host conference call on Wednesday, March 17 at 8:30 am EST First anti-tumor activity observed in heavily pre-treated solid cancer patients during early phases of dose…